What recent pembrolizumab/enfortumab vedotin data mean for treatment of metastatic urothelial cancer

In this video, Jonathan E. Rosenberg, MD, discusses the implications of the findings of the ESMO Congress 2022 abstract, “Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC).” Rosenberg is chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, and Enno W. Ercklentz Chair at Memorial Sloan Kettering Cancer Center in New York, New York.